Conclusion:Patients who received the CAPOX-based perioperative regimen showed favorable survival. CAPOX might represent an option for patients eligible for perioperative chemotherapy. A prospective randomized study is ongoing to confirm these results.Legal entity responsible for the study: The author.

Background: Trifluridine/tipiracil hydrochloride has shown to improve progressionfree survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC). Exploratory analysis suggested that patients with good prognostic characteristics GPC (18 months since first diagnosis) carry better prognosis vs. poor prognostic characteristics (PPC). We report the Greater Manchester experience of the use of TFT.Methods: All consecutive patients who received TFT between August 2016 and August 2019 were included. Data were collected from electronic records. Univariate survival analysis was performed with Kaplan-Meier curve and log-rank test. Cox regression was used for multivariable analysis. Conclusion:Capecitabine associated with mitomycin and SIB-IMRT is a treatment as effective and safer than 5-FU-based chemotherapy for locally SCCAC.

Conclusion: Elevated postoperative CEA following resection of CRC predicted relapse. However, high preoperative CEA levels that normalized after CRC surgery was not associated with higher relapse.Legal entity responsible for the study: Department of medical oncology.